Volrustomig + Pemetrexed + Carboplatin + Cisplatin + Nivolumab + Ipilimumab
Phase 3Recruiting 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Pleural Mesothelioma
Conditions
Unresectable Pleural Mesothelioma
Trial Timeline
Nov 9, 2023 โ Nov 16, 2028
NCT ID
NCT06097728About Volrustomig + Pemetrexed + Carboplatin + Cisplatin + Nivolumab + Ipilimumab
Volrustomig + Pemetrexed + Carboplatin + Cisplatin + Nivolumab + Ipilimumab is a phase 3 stage product being developed by AstraZeneca for Unresectable Pleural Mesothelioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06097728. Target conditions include Unresectable Pleural Mesothelioma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06097728 | Phase 3 | Recruiting |
Competing Products
20 competing products in Unresectable Pleural Mesothelioma